Marfan syndrome: Clinical manifestations, pathophysiology and new outlook on drug therapy;Síndrome de Marfan: Manifestações clínicas, fisiopatologia e novas perspectivas da terapêutica farmacológica

Revista Portuguesa de Cardiologia

Volumn 29, Issue 6, 2010, Pages 1021-1036

  Lebreiro, Ana ^a   Martins, Elisabete ^a   Cruz, Cristina ^a   Almeida, Jorge ^a   Maciel, Maria Júlia ^a   Cardoso, José Carlos ^a   Lima, Cassiano Abreu ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Clinical manifestations; Drug therapy; Marfan syndrome; Pathophsiology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ENALAPRIL; FIBRILLIN 1; LOSARTAN; MATRIX PROTEIN; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PERINDOPRIL; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA;

AORTA ANEURYSM; ARTERIAL WALL THICKNESS; CLINICAL FEATURE; DRUG EFFICACY; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; MARFAN SYNDROME; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; REVIEW; SIGNAL TRANSDUCTION; THORACIC AORTA ANEURYSM;

CARDIOVASCULAR DISEASES; HUMANS; MARFAN SYNDROME;

EID: 77957716189     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26.
2. Mc KV. The cardiovascular aspects of Marfan's syndrome: a heritable disorder of connective tissue. Circulation 1955;11:321-42.
3. Jortner R, Shahin W, Eshkol D, Gueron M, Levy MJ. Cardiovascular manifestations and surgery for Marfan's syndrome. Dis Chest 1969;56:24-30.
4. Halpern BL, Char F, Murdoch JL, Horton WB, McKusick VA. A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J 1971;129:123-9.
5. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-41. (Pubitemid 24136056)
6. Dietz HC, Loeys B, Carta L, Ramirez F. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet 2005;139C:4-9.
7. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004;36:855-60.
8. Mizuguchi T, Matsumoto N. Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J Hum Genet 2007;52:1-12.
9. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407-11.
10. Jones JA, Spinale FG, Ikonomidis JS. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res 2009;46:119-37.
11. Ikonomidis JS, Jones JA, Barbour JR, et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysMFS of patients with Marfan syndrome. Circulation 2006;114:1365-70.
12. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21.
13. Chung AW, Yang HH, RadoMFSki MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res 2008;102:e73-85.
14. Judge DP, Dietz HC. Marfan's syndrome. Lancet 2005;366:1965-76.
15. Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet 2007;15:724-33.
16. Robinson PN, BooMFS P. The molecular pathogenesis of the Marfan syndrome. Cell Mol Life Sci 2001;58:1698-707.
17. Sisk HE, Zahka KG, Pyeritz RE. The Marfan syndrome in early childhood: analysis of 15 patients diagnosed at less than 4 years of age. Am J Cardiol 1983;52:353-8.
18. Rozendaal L, Groenink M, Naeff MFS, et al. Marfan syndrome in children and adolescents: an adjusted nomogram for screening aortic root dilatation. Heart 1998;79:69-72.
19. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005;111:e150-7.
20. Nataatmadja M, West J, West M. Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm. Circulation 2006;114:1371-7. (Pubitemid 44297178)
21. Vitarelli A, Conde Y, Cimino E, et al. Aortic wall mechanics in the Marfan syndrome assessed by transesophageal tissue Doppler echocardiography. Am J Cardiol 2006;97:571-7.
22. Sandor GG, Hishitani T, Petty RE, et al. A novel Doppler echocardiographic method of measuring the biophysical properties of the aorta in pediatric patients. J Am Soc Echocardiogr 2003;16:745-50.
23. Bradley TJ, Potts JE, Potts MT, DeSouza AM, Sandor GG. Echocardiographic Doppler assessment of the biophysical properties of the aorta in pediatric patients with the Marfan syndrome. Am J Cardiol 2005;96:1317-21.
24. Bunton TE, Biery NJ, Myers L, Gayraud B, Ramirez F, Dietz HC. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001;88:37-43.
25. Baumgartner D, Baumgartner C, Schermer E, et al. Different patterns of aortic wall elasticity in patients with Marfan syndrome: a noninvasive follow-up study. J Thorac Cardiovasc Surg 2006;132:811-9.
26. Elefteriades JA. Natural history of thoracic aortic aneurysMFS: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002;74:S1877-80; discussion S92-8.
27. David TE, Feindel CM. An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg 1992;103:617-21; discussion 22.
28. Birks EJ, Webb C, Child A, Radley-Smith R, Yacoub MH. Early and long-term results of a valve-sparing operation for Marfan syndrome. Circulation 1999;100:1129-35.
29. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-81.
30. Beroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C. UMD (Universal mutation database): a generic software to build and analyze locus-specific databases. Hum Mutat 2000;15:86-94.
31. Ramirez F, Sakai LY, Rifkin DB, Dietz HC. Extracellular microfibrils in development and disease. Cell Mol Life Sci 2007;64:2437-46.
32. Robinson PN, BooMFS P, Katzke S, et al. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 2002;20:153-61.
33. Waldmuller S, Muller M, Warnecke H, et al. Genetic testing in patients with aortic aneurysMFS/dissections: a novel genotype/phenotype correlation? Eur J Cardiothorac Surg 2007;31:970-5.
34. Matyas G, Alonso S, Patrignani A, et al. Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome. Hum Genet 2007;122:23-32.
35. Summers KM, West JA, Peterson MM, Stark D, McGill JJ, West MJ. Challenges in the diagnosis of Marfan syndrome. Med J Aust 2006;184:627-31.
36. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006;355:788-98.
37. Johnson PT, Chen JK, Loeys BL, Dietz HC, Fishman EK. Loeys-Dietz syndrome: MDCT angiography findings. AJR Am J Roentgenol 2007;189:W29-35.
38. Ramirez F, Dietz HC. Fibrillin-rich microfibrils: Structural determinants of morphogenetic and homeostatic events. J Cell Physiol 2007;213:326-30.
39. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM. Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 2007;176:355-67.
40. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27. (Pubitemid 35203598)
41. Chung AW, Au Yeung K, Sandor GG, Judge DP, Dietz HC, van Breemen C. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res 2007;101:512-22.
42. Aziz F, Kuivaniemi H. Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm. Ann Vasc Surg 2007;21:392-401.
43. Lindholt JS, Vammen S, Fasting H, Henneberg EW, Heickendorff L. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysMFS. A preliminary study. Eur J Vasc Endovasc Surg 2000;20:281-5.
44. Monaco M, Stassano P, Di Tommaso L, Iannelli G. Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysMFS. J Thorac Cardiovasc Surg 2007;134:925-31.
45. Lorelli DR, Jean-Claude JM, Fox CJ, et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. J Vasc Surg 2002;35:916-22.
46. Sangiorgi G, D'Averio R, Mauriello A, et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001;104:I288-95.
47. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999;83:1364-8.
48. Selamet Tierney ES, Feingold B, Printz BF, et al. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 2007;150:77-82.
49. Gersony DR, McClaughlin MA, Jin Z, Gersony WM. The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. Int J Cardiol 2007;114:303-8.
50. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005;95:1125-7.
51. Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007;298:1539-47.
52. Nagashima H, Sakomura Y, Aoka Y, et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 2001;104:1282-7.
53. Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007;154:624-31.
54. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC, 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358:2787-95.